IRB Advisor – January 1, 2017
January 1, 2017
View Issues
-
Clinical Trial Addresses the Tricky Process of Revealing Genetic Risk Factors for Alzheimer’s
Genetic research that could prevent or treat Alzheimer’s are under study. The caveat is that the human subjects recruited into trials must be willing to know if they carry the DNA markers that may predispose them to subsequent dementia.
-
Research on Brain Scan Risk of Alzheimer’s an Ethical Challenge
While different than genetic signs for dementia, biomarker information found in research brain scans also can suggest heightened risk for developing Alzheimer’s disease, and thus the disclosure or withholding of results raises ethical questions for IRBs and investigators.
-
Meeting Management ABCs From an Expert IRB Chair
After 32 years as an IRB member and 20 years as chair, one IRB expert says the key to IRB meeting success could be boiled down to one word: Respect.
-
When it was Time to Standardize, IRB Went With a P&G Committee
Collaboration and consolidation of IRBs likely will be an ongoing trend that necessitates action to reduce problems and improve streamlining — in other words, best practices.
-
IRB Designs Process to Separate QI from HSR
The most commonly asked question of the Intermountain Healthcare IRB in Salt Lake City has been: “Is this quality improvement or is it research?”
-
People with Mental Illness Often Excluded from Clinical Trials
If a medication for major depression has a dangerous adverse interaction with a different medication that’s being studied in a clinical trial, will it be discovered by researchers and reported in the literature? Not likely, if no one enrolled in the study has major depression.